Biological
Monoclonal antibody hu3S193
Monoclonal antibody hu3S193 is a biological therapy with 4 clinical trials. Historical success rate of 25.0%.
Total Trials
4
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
25.0%
Based on 1 completed trials
Completion Rate
25%(1/4)
Active Trials
0(0%)
Results Posted
400%(4 trials)
Terminated
3(75%)
Phase Distribution
Ph phase_1
3
75%
Ph phase_2
1
25%
Phase Distribution
3
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 2Efficacy & side effects
1(25.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
25.0%
1 of 4 finished
Non-Completion Rate
75.0%
3 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(1)
Terminated(3)
Detailed Status
Terminated3
Completed1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
25.0%
Most Advanced
Phase 2
Trials by Phase
Phase 13 (75.0%)
Phase 21 (25.0%)
Trials by Status
completed125%
terminated375%
Recent Activity
0 active trials
Showing 4 of 4
terminatedphase_1
Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer
NCT00006046
completedphase_1
Monoclonal Antibody Therapy in Treating Patients With Progressive Small Cell Lung Cancer (SCLC)
NCT00084799
terminatedphase_1
Monoclonal Antibody Therapy in Treating Patients Scheduled for Surgery to Remove Ovarian Cancer
NCT00006099
terminatedphase_2
Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer
NCT01137071
Clinical Trials (4)
Showing 4 of 4 trials
NCT00006046Phase 1
Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer
NCT00084799Phase 1
Monoclonal Antibody Therapy in Treating Patients With Progressive Small Cell Lung Cancer (SCLC)
NCT00006099Phase 1
Monoclonal Antibody Therapy in Treating Patients Scheduled for Surgery to Remove Ovarian Cancer
NCT01137071Phase 2
Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer
All 4 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 4